[1]韩春凤,王 轩.支气管哮喘的药物治疗研究[J].医学信息,2021,34(18):63-65.[doi:10.3969/j.issn.1006-1959.2021.18.017]
　HAN Chun-feng,WANG Xuan.Study on the Drug Treatment of Bronchial Asthma[J].Medical Information,2021,34(18):63-65.[doi:10.3969/j.issn.1006-1959.2021.18.017]
点击复制

支气管哮喘的药物治疗研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年18期
页码:
63-65
栏目:
综述
出版日期:
2021-09-18

文章信息/Info

Title:
Study on the Drug Treatment of Bronchial Asthma
文章编号:
1006-1959（2021）18-0063-03
作者:
韩春凤1; 王 轩2
天津医科大学宝坻临床学院/天津市宝坻区人民医院药剂科1，急诊科2，天津 301800
Author(s):
HAN Chun-feng1; WANG Xuan2
Department of Pharmacy1,Department of Emergency2,Tianjin Medical University Baodi Clinical College/Tianjin Baodi People’s Hospital,Tianjin 301800,China
关键词:
支气管哮喘; 糖皮质激素; β2受体激动剂; 细胞粘附分子抑制剂
Keywords:
Bronchial asthma; Glucocorticoid; β2 receptor agonist; Cell adhesion molecule inhibitor
分类号:
R562.2
DOI:
10.3969/j.issn.1006-1959.2021.18.017
文献标志码:
A
摘要:
支气管哮喘是一种以气道慢性炎症为主要特征的呼吸系统疾病，其发病机制复杂，与携带致病基因、环境危险因素、病史等因素相关。患者广泛表现为反复发作性哮喘、气急、胸闷、咳嗽等症状，严重影响其生活质量和生命安全。随着研究的不断深入，支气管哮喘的治疗方案不断更新，药物种类也不断增加。如何科学合理选择药物，在较短时间内控制哮喘症状，减轻患者痛苦成为临床的研究重点。为此，本文主要就支气管哮喘的药物治疗研究进行综述，以促进支气管哮喘治疗的规范化。
Abstract:
Bronchial asthma is a respiratory disease characterized by chronic airway inflammation. Its pathogenesis is complex and is related to the carrying of pathogenic genes, environmental risk factors, medical history and other factors.Patients are widely presented with symptoms such as recurrent asthma, shortness of breath, chest tightness, and cough, which seriously affect their quality of life and life safety.With the continuous deepening of research, the treatment plan of bronchial asthma is constantly updated, and the types of drugs are also increasing.How to choose drugs scientifically and rationally, control asthma symptoms in a relatively short period of time, and alleviate the suffering of patients has become the focus of clinical research.For this reason, this article mainly reviews the drug treatment research of bronchial asthma, in order to promote the standardization of bronchial asthma treatment.

参考文献/References:

[1]Battaglia S,Cardillo I,Lavorini F,et al.Safety Considerations of Inhaled Corticosteroids in the Elderly[J].Drugs&Aging,2014,31(11):787-796.[2]马锦芳,郑劲平.环索奈德粉雾剂治疗支气管哮喘的临床疗效观察[J].海峡药学,2015,8(1):129-131.[3]陈涛,管琼芬,周乐清.沙美特罗替卡松联合布地奈德治疗支气管哮喘的临床疗效观察[J].实用心脑肺血管病杂志,2014,22(12):72-73.[4]韩飞.小剂量糖皮质激素布地奈德吸入治疗支气管哮喘的效果[J].现代诊断与治疗,2019,30(9):1437-1438. [5]陈兰燕.茶碱类药物在支气管哮喘治疗中的合理应用[J].中国实用医药,2014,9(23):189-190.[6]Reddel HK,Bateman ED,Becker A,et al.A summary of the new GINA strategy：a roadmap to asthma control[J].Eur Respir J,2015,46(3):622-639.[7]Sakata Y,Okamoto T,Oshio K,et al.Dietary supplementation with shiikuwasha extract attenuates dexamethasone-induced skeletal muscle atrophy in aged rats[J].Springer Plus,2016,5(1):1-8.[8]韩迪,张晶,段江涛,等.β2受体激动剂治疗支气管哮喘的临床观察[J].中国现代药物应用,2014,5(4):100.[9]吴竟竟.中医中药治疗慢性支气管哮喘60例临床疗效分析[J].中国医药指南,2014,11(4):602-603.[10]帅艳平.支气管哮喘治疗中小剂量糖皮质激素布地奈德吸入的应用观察[J].基层医学论坛,2019,23(10):1476-1477. [11]Manoharan A,Morrison AE,Lipworth BJ.Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD[J].Lung,2016,194(2):1-8.[12]黎亮,谭婷.地塞米松与泼尼松治疗儿童哮喘急性发作疗效与安全性比较的系统评价[J].中国医院用药评价与分析,2018,18(11):1532-1535. [13]宁小平,何东阳,戴广标.舒利迭单用与合用孟鲁司特对老年哮喘的实效性对比[J].临床医学,2016,36(3):45-46．[14]李刘征.硫酸沙丁胺醇和茶碱缓释片治疗急性老年哮喘的疗效[J].中国继续医学教育,2017,9(22):177-178.[15]史存才.茶碱类药物在支气管哮喘治疗中的应用分析[J].中国实用医药,2014,9(5):178-179.[16]李晓芸,刘蕊,李志松.穴位药物注射联合西药对支气管哮喘急性发作期患者肺功能的影响[J].医学综述,2019(7):1452-1456.[17]李翠萍,王石.β2-受体激动剂联合吸入糖皮质激素治疗持续性哮喘的临床疗效分析[J].中国医药科学,2014(33):55-57.[18]杨洪涛,陈哲,宋爱芹.舒利迭联合孟鲁司特治疗支气管哮喘急性发作的临床疗效及对肺功能指标的影响[J].贵州医药,2018,42(1):41-43．[19]胡祥坤,潘春香.舒利迭气雾剂吸入联合孟鲁司特口服治疗支气管哮喘的疗效及对肺功能指标的影响[J].中国民康医学,2019,31(6):4-5．[20]Nakao R,Yamamoto S,Yasumoto Y,et al.Dosing schedule dependent attenuation of dexamethasone-induced muscle atrophy in mice[J].Chronobiology Int,2014,31(4):506-514.

相似文献/References:

[1]钟时嘉.亚急性甲状腺炎的临床分析[J].医学信息,2018,31(01):181.[doi:10.3969/j.issn.1006-1959.2018.01.073]
　ZHONG Shi-jia.Clinical Analysis of Subacute Thyroiditis[J].Medical Information,2018,31(18):181.[doi:10.3969/j.issn.1006-1959.2018.01.073]
[2]唐培渊,宋俊峰,秦克乐,等.难治性特发性血小板减少性紫癜的治疗进展[J].医学信息,2018,31(05):42.[doi:10.3969/j.issn.1006-1959.2018.05.016]
　TANG Pei-yuan,SONG Jun-feng,QIN Ke-le,et al.Progress in Treatment of Refractory Idiopathic Thrombocytopenic Purpura[J].Medical Information,2018,31(18):42.[doi:10.3969/j.issn.1006-1959.2018.05.016]
[3]苗艳茹.甲巯咪唑与糖皮质激素联合治疗甲状腺功能亢进症合并症的效果分析[J].医学信息,2018,31(05):136.[doi:10.3969/j.issn.1006-1959.2018.05.048]
　MIAO Yan-ru.Analysis of Effects of Methimazole and Glucocorticoids on Complications of Hyperthyroidism[J].Medical Information,2018,31(18):136.[doi:10.3969/j.issn.1006-1959.2018.05.048]
[4]焦龙龙,郭悦鹏.初诊哮喘患者的呼出气一氧化氮与大小气道功能的 相关性及临床价值分析[J].医学信息,2018,31(06):70.[doi:10.3969/j.issn.1006-1959.2018.06.022]
　JIAO Long-long,GUO Yue-peng.Correlation and Clinical Value Analysis of Exhaled Nitric Oxide and Airway Function in Patients with Newly Diagnosed Asthma[J].Medical Information,2018,31(18):70.[doi:10.3969/j.issn.1006-1959.2018.06.022]
[5]康 凯,郑继伟,王 闰.糖皮质激素治疗甲亢伴浸润性突眼的疗效分析[J].医学信息,2018,31(08):103.[doi:10.3969/j.issn.1006-1959.2018.08.033]
　KANG Kai,ZHENG Ji-wei,WANG Run.Efficacy of Glucocorticoids in the Treatment of Hyperthyroidism with Infiltrating Exophthalmos[J].Medical Information,2018,31(18):103.[doi:10.3969/j.issn.1006-1959.2018.08.033]
[6]刘玉振.孟鲁司特治疗支气管哮喘的临床研究[J].医学信息,2018,31(10):140.[doi:10.3969/j.issn.1006-1959.2018.10.047]
　LIU Yu-zhen.Clinical Study of Montelukast in the Treatment of Bronchial Asthma[J].Medical Information,2018,31(18):140.[doi:10.3969/j.issn.1006-1959.2018.10.047]
[7]赵 维,廖荣宏,王爱华.糖皮质激素治疗心力衰竭疗效与安全性的Meta分析[J].医学信息,2018,31(14):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
　ZHAO Wei,LIAO Rong-hong,WANG Ai-hua.Meta-analysis of the Efficacy and Safety of Glucocorticoids in the Treatment of Heart Failure[J].Medical Information,2018,31(18):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
[8]井庆彦.治未病三伏贴对支气管哮喘缓解期患者 冬病夏治的疗效观察[J].医学信息,2018,31(17):143.[doi:10.3969/j.issn.1006-1959.2018.17.045]
　JING Qing-yan.Therapeutic Effect of Preventive Treatment of Disease of Sanfu Paster on Summer Treatment of Winter Disease in Patients with Bronchial Asthma[J].Medical Information,2018,31(18):143.[doi:10.3969/j.issn.1006-1959.2018.17.045]
[9]刘广涛,关凤军,董 晨.原发性肾病综合征患儿肾组织P-gp170蛋白和mRNA表达与临床病理及预后的关系[J].医学信息,2018,31(21):61.[doi:10.3969/j.issn.1006-1959.2018.21.017]
　LIU Guang-tao,GUAN Feng-jun,DONG Chen.Relationship between the Expression of p-gp170 Protein and mRNA in Renal Tissue of Children with Primary Nephrotic Syndrome and Clinical Pathology and Prognosis[J].Medical Information,2018,31(18):61.[doi:10.3969/j.issn.1006-1959.2018.21.017]
[10]赵 静,陈华琴,张 宁,等.血清骨膜蛋白和脂联素联检诊断儿童支气管哮喘价值研究[J].医学信息,2018,31(21):71.[doi:10.3969/j.issn.1006-1959.2018.21.019]
　ZHAO Jing,CHEN Hua-qin,ZHANG Ning,et al.Diagnostic Value of Serum Periosteal Protein and Adiponectin in Children with Bronchial Asthma[J].Medical Information,2018,31(18):71.[doi:10.3969/j.issn.1006-1959.2018.21.019]

更新日期/Last Update: 1900-01-01